Prevnar Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The prevnar market research report is one of a series of new reports that provides prevnar market statistics, including prevnar industry global market size, regional shares, competitors with a prevnar market share, detailed prevnar market segments, market trends and opportunities, and any further data you may need to thrive in the prevnar industry. This prevnar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the requirement of adult immunization, outbreak of antibiotic-resistant variants, rising urbanization, epidemiological shifts, and rising of routine adult vaccination. Major trends in the forecast period include advances in conjugate vaccine technology, integration with universal immunization schedule, use of predictive analytics, use of telehealth for vaccine education, and development of needle-free vaccine options.

The growing prevalence of pneumococcal diseases is expected to drive the expansion of the prevnar market in the coming years. Pneumococcal diseases, caused by streptococcus pneumoniae, range from mild conditions such as sinusitis and otitis media to severe illnesses such as pneumonia, meningitis, and sepsis. Factors contributing to the rising prevalence of these diseases include increasing antibiotic resistance, an aging population with weakened immune systems, and inadequate vaccination coverage. Prevnar is a pneumococcal vaccine designed to prevent infections caused by streptococcus pneumoniae, including pneumonia, meningitis, and bloodstream infections, by stimulating the immune system to protect against multiple pneumococcal strains. For example, in May 2024, Statens Serum Institut, a medical laboratory based in Denmark, reported that invasive pneumococcal disease cases rose from 553 in 2022 to 622 in 2023. This growing prevalence of pneumococcal diseases is expected to fuel the demand for prevnar market.

A key trend in the prevnar market is the emphasis on obtaining regulatory approvals to maintain market leadership. Regulatory approvals are essential for ensuring the vaccine's safety, efficacy, and quality, thus facilitating its widespread use. For instance, in April 2023, Pfizer Inc., a US-based pharmaceutical company, received FDA approval for PREVNAR 20, a 20-valent Pneumococcal Conjugate Vaccine. This vaccine is approved for the prevention of invasive pneumococcal disease (IPD) caused by the 20 streptococcus pneumoniae serotypes it covers in infants and children aged 6 weeks to 17 years, and for preventing otitis media in infants aged 6 weeks to 5 years, caused by the seven original serotype conjugates in prevnar.

In November 2023, Pfizer Inc. entered into a partnership with Beijing Keyoceanmed Pharmaceutical Co., Ltd. to distribute and promote Prevenar 13 in mainland China. This collaboration leverages Keyocean’s expertise in warehousing, distribution, and supply chain management to expand access to Prevenar 13 throughout China. Beijing Keyoceanmed is a China-based pharmaceutical company specializing in the production of innovative drugs.

The key company operating in the prevnar market is Pfizer Inc.

North America was the largest region in the prevnar market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prevna report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prevnar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Prevnar is a series of vaccines designed to protect against pneumococcal infections caused by the bacterium streptococcus pneumoniae. These infections can result in severe diseases such as pneumonia, meningitis, sepsis, and ear infections, particularly affecting vulnerable groups such as infants, the elderly, and individuals with weakened immune systems. The Prevnar vaccines utilize conjugate technology, which links polysaccharides to a protein.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main formulations of prevnar are prevnar 13 and prevnar 20. The prevnar 13 vaccine targets 13 types of pneumococcal bacteria and is commonly used to immunize both children and adults against serious infections such as pneumonia and meningitis. Its indications include pneumonia, meningitis, sepsis, and other related conditions, and it is distributed through partner companies, non-governmental organizations, and government authorities. The vaccine is administered to various groups, including pediatric, geriatric, and adult populations.

The prevnar market consists of sales of prevnar 13, prevnar 20, and prevnar 7. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from selling goods or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.